<?release-delay 0|0 ?><?iucr-info access=oa?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Crystallogr Sect F Struct Biol Cryst Commun</journal-id><journal-id journal-id-type="publisher-id">Acta Cryst. F</journal-id><journal-title>Acta Crystallographica Section F: Structural Biology and Crystallization Communications</journal-title><issn pub-type="epub">1744-3091</issn><publisher><publisher-name>International Union of Crystallography</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ll5172</article-id><article-id pub-id-type="doi">10.1107/S1744309108037925</article-id><article-id pub-id-type="coden">ACSFCL</article-id><article-id pub-id-type="pii">S1744309108037925</article-id><article-categories><subj-group subj-group-type="heading"><subject>Crystallization Communications</subject></subj-group></article-categories><title-group><article-title>Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon &#x003b1;-2A</article-title><alt-title>Interferon &#x003b1;-2A&#x02013;Fab fragment complex</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oganesyan</surname><given-names>Vaheh</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Damschroder</surname><given-names>Melissa M.</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Cook</surname><given-names>Kimberly E.</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Herren</given-names></name><xref ref-type="aff" rid="a">a</xref><xref ref-type="corresp" rid="cor">*</xref></contrib><contrib contrib-type="author"><name><surname>Dall&#x02019;Acqua</surname><given-names>William F.</given-names></name><xref ref-type="aff" rid="a">a</xref><xref ref-type="corresp" rid="cor">*</xref></contrib><aff id="a"><label>a</label>Department of Antibody Discovery and Protein Engineering, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, <country>USA</country></aff></contrib-group><author-notes><corresp id="cor">Correspondence e-mail: <email>wuh@medimmune.com</email>, <email>dallacquaw@medimmune.com</email></corresp></author-notes><pub-date pub-type="collection"><day>1</day><month>1</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>25</day><month>12</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>1</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="collection"/>. --><volume>65</volume><issue>Pt 1</issue><issue-id pub-id-type="publisher-id">f090100</issue-id><fpage>14</fpage><lpage>16</lpage><history><date date-type="received"><day>22</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; Oganesyan et al. 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/uk/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.</p></license></permissions><self-uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1107/S1744309108037925">A full version of this article is available from Crystallography Journals Online.</self-uri><abstract abstract-type="toc"><p>Crystals of the complex between the Fab fragment of a human anti-interferon &#x003b1; therapeutic antibody and human interferon &#x003b1;-2A have been obtained and diffracted to 3.0&#x02005;&#x000c5; resolution.</p></abstract><abstract><p>Recombinant human interferon &#x003b1;-2A (rhIFN-&#x003b1;-2A) has been crystallized in complex with the recombinantly produced Fab fragment of a therapeutic monoclonal antibody (MEDI545; IgG1/&#x003ba;) which targets several human inter&#x000ad;feron &#x003b1; subtypes. This constitutes the first reported crystals of a human type I interferon bound to an antibody. The orthorhombic crystals belonged to either space group <italic>I</italic>222 or <italic>I</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, with unit-cell parameters <italic>a</italic> = 134.82, <italic>b</italic>&#x000a0;=&#x000a0;153.26, <italic>c</italic>&#x000a0;=&#x000a0;163.49&#x02005;&#x000c5;. The diffraction of the crystals extended to 3.0&#x02005;&#x000c5; resolution. The asymmetric unit contained two Fab&#x02013;rhIFN-&#x003b1;-2A complexes. This corresponded to a crystal volume per protein weight (<italic>V</italic><sub>M</sub>) of 3.02&#x02005;&#x000c5;<sup>3</sup>&#x02005;Da<sup>&#x02212;1</sup> and a solvent content of 59.3%. The corresponding three-dimensional structure is expected to shed light on the mechanism of action of MEDI545 and the molecular basis of its specificity.</p></abstract><kwd-group><kwd>interferon &#x003b1;-2A</kwd><kwd>antibodies</kwd><kwd>Fab fragments</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction" id="sec1"><label>1.</label><title>Introduction</title><p>Type I interferons (IFNs) are a family of cytokines that are expressed from over 15 functional genes and include IFN-&#x003b1;, IFN-&#x003b2;, IFN-&#x003c4;, IFN-&#x000ad;&#x003ba;, IFN-&#x0220a;, IFN-&#x003b4; and IFN-&#x003c9;. Interferons, in particular IFN-&#x003b1; and IFN-&#x003b2;, have historically been characterized in terms of their role in modulating the responses of mammalian hosts to infections (Isaacs &#x00026; Lindenmann, 1957<xref ref-type="bibr" rid="bb6"> &#x025b6;</xref>; Gresser <italic>et al.</italic>, 1976<xref ref-type="bibr" rid="bb5"> &#x025b6;</xref>; Alsharifi <italic>et al.</italic>, 2008<xref ref-type="bibr" rid="bb1"> &#x025b6;</xref>). How&#x000ad;ever, it is becoming increasingly clear that they also play a key role in immune regulation and autoimmune diseases (Baccala <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb2"> &#x025b6;</xref>; Theofilopoulos <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb14"> &#x025b6;</xref>). The IFN-&#x003b1; family alone comprises at least 13 different subtypes (Foster &#x00026; Finter, 1998<xref ref-type="bibr" rid="bb4"> &#x025b6;</xref>) and is thought to play a role in systemic lupus erythematosus (SLE), type I diabetes, Sj&#x000f6;gren&#x02019;s syndrome and thyroid diseases (Selmi <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb13"> &#x025b6;</xref>). This attractive targeting potential led to the development by MedImmune of MEDI545, a fully human monoclonal antibody which exhibits binding to multiple IFN-&#x003b1; subtypes. MEDI545 is currently undergoing several human clinical trials for various indications such as lupus, chronic plaque psoriasis, dermatomyositis and poliomyelitis (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>).</p><p>In an effort to better understand the molecular basis of the recognition of IFN-&#x003b1; molecules by MEDI545, we set out to solve the X-ray crystal structure of the complex between the Fab fragment of this antibody and human IFN-&#x003b1;-2A. Three type I human interferon structures have previously been determined using either X-ray crystallography or NMR. These correspond to human IFN-&#x003b1;-2a, IFN-&#x000ad;&#x003b1;-2b and IFN-&#x003b2; (Radhakrishnan <italic>et al.</italic>, 1996<xref ref-type="bibr" rid="bb12"> &#x025b6;</xref>; Karpusas <italic>et al.</italic>, 1997<xref ref-type="bibr" rid="bb8"> &#x025b6;</xref>; Klaus <italic>et al.</italic>, 1997<xref ref-type="bibr" rid="bb9"> &#x025b6;</xref>). Here, the first reported diffracting crystals of a human type I interferon bound to an antibody are described and characterized.</p></sec><sec sec-type="materials|methods" id="sec2"><label>2.</label><title>Materials and methods</title><sec id="sec2.1"><label>2.1.</label><title>Expression and purification of MEDI545 Fab and rhIFN-&#x003b1;-2a</title><p>The heavy and light chains of the Fab fragment of MEDI545 (IgG1/&#x003ba;) were cloned into a mammalian expression vector. More precisely, each chain was placed under the control of its own human cytomegalovirus major immediate early (hCMVie) promoter and enhancer (described in Boshart <italic>et al.</italic>, 1985<xref ref-type="bibr" rid="bb3"> &#x025b6;</xref>). Each of those two genes also incorporated an SV40 poly-A sequence to allow proper pro&#x000ad;cessing of its 3&#x02032; end. In this system, a human &#x003b3;1 chain truncated at position Lys235 (according to the Kabat numbering convention; Kabat <italic>et al.</italic>, 1991<xref ref-type="bibr" rid="bb7"> &#x025b6;</xref>) is secreted along with a human &#x003ba; chain (Oganesyan <italic>et al.</italic>, 2008<xref ref-type="bibr" rid="bb10"> &#x025b6;</xref>). The construct was then transiently transfected into human embryonic kidney (HEK) 293 cells using Lipofectamine (Invitrogen, Carlsbad, California, USA) and standard protocols. MEDI545 Fab was typically harvested 72, 144 and 216&#x02005;h post-transfection. Conditioned media containing the soluble Fab fragment were then dialyzed against 50&#x02005;m<italic>M</italic> sodium acetate pH 5.2, 20&#x02005;m<italic>M</italic> NaCl and purified using a HiTrap HP SP column in a NaCl gradient according to the manufacturer&#x02019;s instructions (GE Healthcare, Piscataway, New Jersey, USA). Purified MEDI545 Fab, typically &#x0003e;95% homogeneous as judged by SDS&#x02013;PAGE, was then concentrated to approximately 30&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup>.</p><p>High-quality nearly 100% homogeneous <italic>Escherichia coli</italic>-expressed recombinant human interferon &#x003b1;-2A (rhIFN-&#x003b1;-2A) was purchased directly from Potomac Affinity Proteins LLC (Rockville, Maryland, USA). The cytokine&#x02019;s mature sequence corresponded to residues 24&#x02013;188 of entry No. P01563 of the Swiss-Prot protein database (<ext-link ext-link-type="uri" xlink:href="http://www.expasy.org">http://www.expasy.org</ext-link>) and included two extra threonine and serine residues on its N-terminal end. MEDI545 Fab and rhIFN-&#x003b1;-2A were mixed in a 1.2:1 molar ratio. The resulting mixture was then adjusted to approximately 10&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup>. The complex was further purified by size-exclusion chromatography using a Superdex S200 column (GE Healthcare) equilibrated with 20&#x02005;m<italic>M</italic> sodium acetate pH 5.2, 20&#x02005;m<italic>M</italic> NaCl at a flow rate of 0.5&#x02005;ml&#x02005;min<sup>&#x02212;1</sup>. After separation from excess MEDI545 Fab, the complex was concentrated to 6.5&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup> using an Amicon YM-30 concentrator (Millipore, Billerica, Massachusetts, USA).</p></sec><sec id="sec2.2"><label>2.2.</label><title>Crystallization screening and optimization</title><p>Sitting-drop crystallization experiments were initially set up in 96-&#x000ad;well plates with conical flat-bottomed drop compartments (Corning 3785; VWR, West Chester, Pennsylvania, USA) using a Phoenix crystallization robot (Art Robbins, Sunnyvale, California, USA). Favorable conditions were initially identified using the following commercially available crystallization screens: Crystal Screen HT, Index Screen, SaltRx (Hampton Research, Aliso Viejo, California, USA) and ProPlex (Molecular Dimensions, Apopka, Florida, USA). For further optimization purposes, a commercially available kit was used (Additive Screen HT; Hampton Research). More particularly, in screening mode the reservoirs and drop compartments of the 96-well plates were filled with 99 and 0.3&#x02005;&#x000b5;l, respectively, of the various screen solutions using the Phoenix robot. 0.3&#x02005;&#x000b5;l of the MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2A complex at a concentration of 6.5&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup> was then added to the drop compartment. In optimization mode, the reservoirs were first filled with 80&#x02005;&#x000b5;l screen solution. 20&#x02005;&#x000b5;l of the various additives were then added and the reservoirs were subjected to five cycles of mixing by aspiration/dispensing. 0.3&#x02005;&#x000b5;l of each reservoir solution was then mixed with 0.3&#x02005;&#x000b5;l of the MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2A complex at a concentration of 6.5&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup> in the drop compartment. Diffraction-quality crystals were grown in hanging drops once optimal conditions had been identified (see &#x000a7;<xref ref-type="sec" rid="sec3"/>3).</p></sec><sec id="sec2.3"><label>2.3.</label><title>X-ray diffraction data collection and processing</title><p>Diffraction data were collected from a single crystal at the Center for Advanced Research in Biotechnology (CARB, University of Maryland Biotechnology Institute, Rockville, Maryland, USA) using a MicroMax-007 rotating-anode generator fitted with an R-AXIS IV<sup>++</sup> imaging plate (Rigaku/MSC, The Woodlands, Texas, USA). The crystal was harvested using a litho-loop and flash-cooled in a liquid-nitrogen stream using an X-stream 2000 cryogenic cooler (Rigaku/MSC). Prior to this step, cryoprotection was achieved by soaking the crystal in 200&#x02005;m<italic>M</italic> NaI, 8&#x02005;m<italic>M</italic> NiCl<sub>2</sub>.6H<sub>2</sub>O, 80&#x02005;m<italic>M</italic> Tris&#x02013;HCl pH 8.5, 16%(<italic>w</italic>/<italic>v</italic>) polyethylene glycol monomethyl ether 2000, 20% glycerol. 240 consecutive images were collected using an oscillation range of 0.5&#x000b0;, a crystal-to-detector distance of 250&#x02005;mm and an exposure time of 600&#x02005;s. The diffraction images were integrated and scaled using <italic>HKL</italic>-2000 (Otwinowski &#x00026; Minor, 1997<xref ref-type="bibr" rid="bb11"> &#x025b6;</xref>).</p></sec></sec><sec sec-type="discussion|interpretation" id="sec3"><label>3.</label><title>Results and discussion</title><p>Crystals of less than 10&#x02005;&#x000b5;m in size and of tetragonal bipyramidal shape appeared during the screening process with Crystal Screen HT under condition H9 [0.01&#x02005;<italic>M</italic> NiCl<sub>2</sub>.6H<sub>2</sub>O, 0.1&#x02005;<italic>M</italic> Tris&#x02013;HCl pH 8.5, 20%(<italic>w</italic>/<italic>v</italic>) polyethylene glycol monomethyl ether 2000] as seen in Fig.&#x000a0;1<xref ref-type="fig" rid="fig1"> &#x025b6;</xref>(<italic>a</italic>). During the optimization process, crystals of similar morphology appeared in almost all of the conditions of the Additive Screen. However, the largest crystals were obtained when using additives B8 (1.0&#x02005;<italic>M</italic> NaI), D3 (0.1&#x02005;<italic>M</italic> spermine&#x02013;HCl) and D4 [0.1&#x02005;<italic>M</italic> cobalt(III) hexammine chloride]. Hanging drops were then set up under those various conditions using 1&#x02005;&#x000b5;l of the MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2A complex at a concentration of 3.5&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup> in 20&#x02005;m<italic>M</italic> sodium acetate pH 5.2, 20&#x02005;m<italic>M</italic> NaCl and 1&#x02005;&#x000b5;l of the appropriate reservoir solutions. Diffraction-quality orthorhombic crystals grew in about 15&#x02005;d when 200&#x02005;m<italic>M</italic> NaI, 8&#x02005;m<italic>M</italic> NiCl<sub>2</sub>.6H<sub>2</sub>O, 80&#x02005;m<italic>M</italic> Tris&#x02013;HCl pH 8.5, 16%(<italic>w</italic>/<italic>v</italic>) polyethylene glycol monomethyl ether 2000 was used as the reservoir solution. They reached dimensions of up to 0.1&#x000a0;&#x000d7;&#x000a0;0.1 &#x000d7; 0.2&#x02005;mm, as seen in Fig. 1<xref ref-type="fig" rid="fig1"> &#x025b6;</xref>(<italic>b</italic>).</p><p>SDS&#x02013;PAGE analysis of these crystals confirmed that they indeed contained the expected complex formed by MEDI545 Fab and the recombinant human interferon &#x003b1;-2A (see Fig. 2<xref ref-type="fig" rid="fig2"> &#x025b6;</xref>). Incidentally, the SDS&#x02013;PAGE profile of MEDI545 Fab also demonstrated the presence of the expected interchain disulfide bond between C&#x003ba;/Cys214 and C<sub>H</sub>1/Cys233 (Kabat numbering; Kabat <italic>et al.</italic>, 1991<xref ref-type="bibr" rid="bb7"> &#x025b6;</xref>) owing to its differential migration pattern under reducing and nonreducing con&#x000ad;ditions (see Fig. 2<xref ref-type="fig" rid="fig2"> &#x025b6;</xref>).</p><p>The diffraction limit of the crystal was 3.0&#x02005;&#x000c5; (see Fig. 3<xref ref-type="fig" rid="fig3"> &#x025b6;</xref>). The possible space groups were determined to be either <italic>I</italic>222 or <italic>I</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, with unit-cell parameters <italic>a</italic> = 134.82, <italic>b</italic> = 153.26, <italic>c</italic> = 163.49&#x02005;&#x000c5;. The asymmetric unit contained two MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2A com&#x000ad;plexes. This corresponded to a <italic>V</italic><sub>M</sub> of 3.02&#x02005;&#x000c5;<sup>3</sup>&#x02005;Da<sup>&#x02212;1</sup> and a solvent content of 59.3%. Data-collection statistics are shown in Table 1<xref ref-type="table" rid="table1"> &#x025b6;</xref>. Structure determination using molecular replacement is currently under way.</p></sec></body><back><ack><p>We are grateful to Potomac Affinity Proteins LLC (Rockville, Maryland, USA) for help in providing rhIFN-&#x003b1;-2A. MEDI545 is a fully human IgG1 anti-interferon &#x003b1; antibody that was generated by Medarex in mice transgenic for human immunoglobulin genes.</p></ack><ref-list><title>References</title><ref id="bb1"><citation citation-type="other">Alsharifi, M., M&#x000fc;llbacher, A. &#x00026; Regner, M. (2008). <italic>Immunol. Cell Biol.</italic><bold>86</bold>, 239&#x02013;245.</citation></ref><ref id="bb2"><citation citation-type="other">Baccala, R., Kono, D. H. &#x00026; Theofilopoulos, A. N. (2005). <italic>Immunol. Rev.</italic><bold>204</bold>, 9&#x02013;26.</citation></ref><ref id="bb3"><citation citation-type="other">Boshart, M., Weber, F., Jahn, G., Dorsch-Hasler, K., Fleckenstein, B. &#x00026; Schaffner, W. (1985). <italic>Cell</italic>, <bold>41</bold>, 521&#x02013;530.</citation></ref><ref id="bb4"><citation citation-type="other">Foster, G. R. &#x00026; Finter, N. B. (1998). <italic>J. Viral. Hepat.</italic><bold>5</bold>, 143&#x02013;152.</citation></ref><ref id="bb5"><citation citation-type="other">Gresser, I., Tovey, M. G., Bandu, M. E., Maury, C. &#x00026; Brouty-Boy&#x000e9;, D. (1976). <italic>J. Exp. Med.</italic><bold>144</bold>, 1305&#x02013;1315.</citation></ref><ref id="bb6"><citation citation-type="other">Isaacs, A. &#x00026; Lindenmann, J. (1957). <italic>Proc. R. Soc. Lond. B Biol. Sci.</italic><bold>147</bold>, 258&#x02013;267.</citation></ref><ref id="bb7"><citation citation-type="other">Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S. &#x00026; Foeller, C. (1991). <italic>Sequences of Proteins of Immunological Interest.</italic> Washington DC: National Institutes of Health.</citation></ref><ref id="bb8"><citation citation-type="other">Karpusas, M., Nolte, M., Benton, C. B., Meier, W., Lipscomb, W. N. &#x00026; Goelz, S. (1997). <italic>Proc. Natl Acad. Sci. USA</italic>, <bold>94</bold>, 11813&#x02013;11818.</citation></ref><ref id="bb9"><citation citation-type="other">Klaus, W., Gsell, B., Labhardt, A. M., Wipf, B. &#x00026; Senn, H. (1997). <italic>J. Mol. Biol.</italic><bold>274</bold>, 661&#x02013;675.</citation></ref><ref id="bb10"><citation citation-type="other">Oganesyan, V., Damschroder, M. M., Leach, W., Wu, H. &#x00026; Dall&#x02019;Acqua, W. F. (2008). <italic>Mol. Immunol.</italic><bold>45</bold>, 1872&#x02013;1882.</citation></ref><ref id="bb11"><citation citation-type="other">Otwinowski, Z. &#x00026; Minor, W. (1997). <italic>Methods Enzymol.</italic><bold>276</bold>, 307&#x02013;326.</citation></ref><ref id="bb12"><citation citation-type="other">Radhakrishnan, R., Walter, L. J., Hruza, A., Reichert, P., Trotta, P. P., Nagabhushan, T. L. &#x00026; Walter, M. R. (1996). <italic>Structure</italic>, <bold>4</bold>, 1453&#x02013;1463.</citation></ref><ref id="bb13"><citation citation-type="other">Selmi, C., Lleo, A., Zuin, M., Podda, M., Rossaro, L. &#x00026; Gershwin, M. E. (2006). <italic>Curr. Opin. Invest. Drugs</italic>, <bold>7</bold>, 451&#x02013;456.</citation></ref><ref id="bb14"><citation citation-type="other">Theofilopoulos, A. N., Baccala, R., Beutler, B. &#x00026; Kono, D. H. (2005). <italic>Annu. Rev. Immunol.</italic><bold>23</bold>, 307&#x02013;336.</citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Crystals of the MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2a complex. (<italic>a</italic>) Screening. The crystals shown were obtained during the initial screening phase using Crystal Screen HT (Hampton Research) under condition H9 [0.01&#x02005;<italic>M</italic> NiCl<sub>2</sub>.6H<sub>2</sub>O, 0.1&#x02005;<italic>M</italic> Tris&#x02013;HCl pH 8.5, 20%(<italic>w</italic>/<italic>v</italic>) polyethylene glycol monomethyl ether 2000]. (<italic>b</italic>) Optimization. The crystals shown grew to dimensions of up to 0.1 &#x000d7; 0.1 &#x000d7; 0.2&#x02005;mm in hanging drops when 1&#x02005;&#x000b5;l reservoir solution [200&#x02005;m<italic>M</italic> NaI, 8&#x02005;m<italic>M</italic> NiCl<sub>2</sub>.6H<sub>2</sub>O, 80&#x02005;m<italic>M</italic> Tris&#x02013;HCl pH 8.5, 16%(<italic>w</italic>/<italic>v</italic>) polyethylene glycol monomethyl ether 2000] was mixed with 1&#x02005;&#x000b5;l of a 3.5&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup> MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2A solution in 20&#x02005;m<italic>M</italic> sodium acetate pH 5.2, 20&#x02005;m<italic>M</italic> NaCl.</p></caption><graphic xlink:href="f-65-00014-fig1"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>SDS&#x02013;PAGE profile of a dissolved crystal of the MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2a complex under reducing and nonreducing conditions. The 4&#x02013;20% gradient gel (BioRad, Hercules, California, USA) was stained with Bio-Safe Coomassie Stain (BioRad). It shows rhIFN-&#x003b1;-2a migrating at around 15 and 20&#x02005;kDa under nonreducing and reducing conditions, respectively. This difference is likely to be attributable to the presence of two internal disulfide bonds, the reduction of which alters the compactness (and thus the migration) of the molecule. The same argument can be applied to the MEDI545 Fab fragment, which migrated slightly under its expected molecular weight of 50&#x02005;kDa under nonreducing conditions. As expected, its heavy and light chains both migrated at 25&#x02005;kDa under reducing conditions.</p></caption><graphic xlink:href="f-65-00014-fig2"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Diffraction image of a MEDI545 Fab&#x02013;rhIFN-&#x003b1;-2a crystal.</p></caption><graphic xlink:href="f-65-00014-fig3"/></fig><table-wrap id="table1" position="float"><label>Table 1</label><caption><title>X-ray diffraction data-collection statistics</title><p>Values in parentheses are for the highest resolution shell.</p></caption><table frame="hsides" rules="groups"><tbody valign="top"><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Wavelength (&#x000c5;)</td><td style="" rowspan="1" colspan="1" align="left" valign="top">1.54</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Resolution (&#x000c5;)</td><td style="" rowspan="1" colspan="1" align="left" valign="top">23.0&#x02013;3.0 (3.11&#x02013;3.0)</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Space group</td><td style="" rowspan="1" colspan="1" align="left" valign="top"><italic>I</italic>222 or <italic>I</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Unit-cell parameters (&#x000c5;)</td><td style="" rowspan="1" colspan="1" align="left" valign="top"><italic>a</italic> = 134.82, <italic>b</italic> = 153.26, <italic>c</italic> = 163.49</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Total reflections</td><td style="" rowspan="1" colspan="1" align="left" valign="top">156727</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Unique reflections</td><td style="" rowspan="1" colspan="1" align="left" valign="top">34084</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Average redundancy</td><td style="" rowspan="1" colspan="1" align="left" valign="top">4.6 (4.3)</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Completeness (%)</td><td style="" rowspan="1" colspan="1" align="left" valign="top">99.8 (99.4)</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top"><italic>R</italic><sub>merge</sub></td><td style="" rowspan="1" colspan="1" align="left" valign="top">0.119 (0.423)</td></tr><tr><td style="" rowspan="1" colspan="1" align="left" valign="top">Mean <italic>I</italic>/&#x003c3;(<italic>I</italic>)</td><td style="" rowspan="1" colspan="1" align="left" valign="top">7.8 (2.7)</td></tr></tbody></table></table-wrap></floats-wrap></article> 